Navigation Links
5 big strides to fight lung disease in our tiniest patients
Date:12/3/2012

December, 4, 2012 Ottawa For Ottawa scientist and neonatologist Dr. Bernard Thbaud, even a major paper that answers five significant questions still doesn't seem quite enough in his determined path to get his laboratory breakthrough into the neonatal intensive care unit (NICU). Dr. Thbaud's proposed therapy would use stem cells from umbilical cords to treat a disease previously thought to be untreatable bronchopulmonary dysplasia, or BPD.

"BPD is a lung disease described 45 years ago in which we have made zero progress. And now, with these cord-derived stem cells there is a true potential for a major breakthrough," says Dr. Thbaud, a senior scientist at the Ottawa Hospital Research Institute and CHEO Research Institute, a neonatologist at CHEO and The Ottawa Hospital, and a professor in the Faculty of Medicine at the University of Ottawa.

"I am confident that we have the talent and the tools here at CHEO and OHRI to find a treatment for BPD. These findings published today are helping us get there," continues Thbaud.

BPD affects approximately 10,000 very premature newborns in Canada and the U.S. every year. The lungs of these infants are not developed enough to sustain them, so they must receive oxygen through a breathing machine. However, this combination of mechanical ventilation and oxygen damages the lungs and stops their development. In addition, longer stays in the NICU for these extremely premature babies affect the normal development of other parts of the body, including the retina, the kidneys and the brain.

Today in the journal Thorax, Dr. Thbaud's team provides significant findings in experiments with newborn rats given oxygen. The lung development of a newborn rat mimics that of a premature baby born at 24 weeks. The five major findings reported in Thorax are:

  1. Stem cells called mesenchymal stromal cells (MSCs) from a human umbilical cord (not the blood) have a protective effect on the lungs when injected into the lungs as they were put on oxygen.
  2. MSCs had a reparative effect when injected two weeks after being on oxygen.
  3. When conditioned media a cell-free substance produced by MSCs was administered instead of MSCs, it was found to have the same protective and reparative effects as the stem cells.
  4. When examined after six months (the equivalent of 40 human years), treated animals had better exercise performance and persistent benefit in lung structure.
  5. MSCs did not adversely affect the long-term health of normal rats. One of the concerns about stem cells is that by promoting cell growth, they may cause cancerous growth. To address this question, Dr. Thbaud gave MSCs to a control group that was not treated with oxygen. When examined after six months, these animals were normal and healthy.

Within two years, Dr. Thbaud wants to be talking about a pilot study with 20 human patients showing that this stem-cell therapy is feasible and safe, and in four years he wants to embark on a randomized control trial. These are all steps in his profound desire to help the babies he sees in the NICU with BPD, and he is confident a treatment will be developed.

"It's going to happen here in Ottawa, but for babies worldwide," says Dr. Thbaud.


'/>"/>

Contact: Paddy Moore
padmoore@ohri.ca
613-737-8899 x73687
Ottawa Hospital Research Institute
Source:Eurekalert  

Related medicine news :

1. Colorful Fruits, Vegetables May Be Key to Cancer-Fighting Diet
2. University of Tennessee study: Unexpected microbes fighting harmful greenhouse gas
3. Virtual reality could help people lose weight, fight prejudice
4. New bacteria to fight against intestinal inflammation
5. Could Cholesterol Treatment Fight Repeat Heart Attack?
6. Recent findings may help to fight melanomas resistance to chemotherapy
7. Short Bursts of Intense Exercise Can Fight Weight Gain: Study
8. Tissue around tumor holds key to fighting triple negative breast cancer
9. FEMA awards $1 Million to WPI to develop groundbreaking toxic gas sensors for firefighters
10. Mayo Clinic researchers identify new enzyme to fight Alzheimers disease
11. An advance toward a flu-fighting nasal spray
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
5 big strides to fight lung disease in our tiniest patients
(Date:12/7/2016)... ... ... A quote from Dr. Edward Hallowell, host of CRN International’s “Distraction” podcast ... glimpse into the mind of those people with ADHD. , Dr. Hallowell, a child ... people with ADHD as having “Ferrari engines for a brain, with bicycle brakes.” , ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff ... located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, ... treatment for a brain tumor. , Jason Bauer and his family are longtime ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm ... Boroughs, is launching a charity drive to raise funds that will benefit the Marine ... of marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry ... through user experience. , BOC Global Events & Training Group is a professional ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer ... trial in patients with unresectable malignant pleural mesothelioma ... (PFS). The data, presented at the 17 th ... Vienna , showed nintedanib plus ... placebo plus pemetrexed/cisplatin, with a significantly improved PFS ...
Breaking Medicine Technology: